Klotho

What is Klotho?

α-Klotho is a single-pass transmembrane protein identified in 1997 by Makoto Kuro-o and colleagues as the product of a gene whose disruption in mice produces a syndrome of accelerated aging. The Nature paper described it as short lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis and emphysema; cognitive impairment in klotho-deficient mice was characterised later and was not part of the 1997 description. The full-length membrane protein (~130 kDa) has two extracellular domains (KL1 and KL2, each ~500–550 amino acids) and functions as an obligatory co-receptor for FGF23. A soluble form (sKlotho, principally KL1 or the KL1+KL2 extracellular ectodomain) circulates in blood, urine, and cerebrospinal fluid, and has distinct functions — it is this soluble form that has attracted interest as a therapeutic target and that underlies the academic work on klotho and cognition — genetic overexpression in mice (Dubal 2014), peripheral injection of an α-klotho fragment (Leon 2017), and a single low dose in aged rhesus monkeys (Castner 2023). The KL-VS heterozygous haplotype (F352V plus C370S) is a well-replicated human genetic variant associated with modestly enhanced cognition and longevity. Despite enormous interest, no Klotho-based therapeutic has FDA approval, and the grey-market 'Klotho peptide' sold to biohackers is of unclear identity and not the recombinant material used in academic research.

What Klotho Is Investigated For

Klotho is one of the most genuinely interesting proteins in aging biology and simultaneously one of the most oversold. The KL-VS heterozygous haplotype is a replicated human genetic variant that confers a real, if modest, cognitive advantage and is associated with longer lifespan in meta-analyses — Arking 2005 and subsequent work is robust. The preclinical cognitive story is often told sloppily, so it is worth separating: Dubal 2014 showed that mice with transgenic systemic overexpression of klotho outperform controls on learning and memory; the peripheral-injection result came three years later, when Leon 2017 showed an α-klotho fragment improved cognition in mice despite not crossing the blood-brain barrier; and Castner 2023 extended this to aged rhesus monkeys, where a single low dose enhanced memory but a high dose did not. That non-monotonic dose-response in the only primate study is the most practically important finding on this page. No FDA-approved Klotho therapeutic exists and recombinant sKL is not on the compounded-peptide or legitimate-supply market. Products sold as 'Klotho peptide' to the biohacker community are of unclear identity — the KL1 and KL2 domains are each ~500–550 amino acids, not the short synthesis-friendly peptides these products typically represent. Serum α-Klotho measurement is clinically relevant in chronic kidney disease monitoring but less informative for healthy-population assessment. The page is positioned as a biology reference with a reality-check on the therapeutic claims circulating in the longevity market.

History & Discovery

Klotho was identified in 1997 by Makoto Kuro-o, working then in Japan, through a fortuitous transgene insertion that disrupted expression of an unknown gene and produced a mouse with dramatically accelerated aging — in the Nature paper's own list, short lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis and emphysema. The gene was named 'klotho' after one of the three Fates in Greek mythology (the spinner of the thread of life). The Nature paper launched the field. The next decade mapped Klotho's two principal functions. Kurosu et al. 2005 Science showed Klotho overexpression extends mouse lifespan and established early mechanistic links to insulin/IGF-1 signaling. Work from several groups identified α-Klotho as the obligatory co-receptor for FGF23, explaining the phosphate-homeostasis phenotype of Klotho-null mice. The KL-VS haplotype was characterized by Arking and colleagues as a functional variant associated with human longevity and cardiovascular phenotypes. The cognitive-aging chapter opened with Dena Dubal's 2014 Cell Reports paper, which established the human KL-VS cognitive-enhancement association and showed that transgenic klotho overexpression improves learning and memory in mice, acting through the NMDA-receptor subunit GluN2B — blocking GluN2B abolished the effect entirely. The step toward a tractable intervention came in 2017, when Leon and colleagues showed that an α-klotho fragment given peripherally reproduced the cognitive benefit. That result carried a puzzle still unresolved: the fragment does not cross the blood-brain barrier, so whatever reaches the brain is a downstream signal rather than the protein itself. Castner 2023 then extended the finding to aged rhesus monkeys, with the important wrinkle that a single low dose worked and a high dose did not. Commercially the field moved ahead of the evidence. Two companies put klotho into humans in 2025–26 outside the conventional regulatory path: Minicircle ran two nonviral plasmid klotho gene-therapy pilots in healthy adults (NCT07216781, and NCT07285629 combining klotho with follistatin) across sites in Austin and Roatán, Honduras, and Klothea Bio registered a Phase 1 lipid-nanoparticle α-klotho mRNA study (NCT07544420) at the same Honduran clinic. All are small, the two gene-therapy pilots are uncontrolled, and none has posted results. The grey-market 'Klotho peptide' industry — selling short synthetic peptides of unclear design to biohackers — has emerged in parallel to the academic work but has no relationship to the recombinant material used in research.

How It Works

Klotho is a protein that plays at least two distinct roles. In the kidney, it helps the body handle phosphate by working with FGF23. In the blood and cerebrospinal fluid, a soluble form circulates and seems to have effects on aging, cognition, and cellular stress resistance. Mice without Klotho age very quickly; mice given extra Klotho live longer and think better. Humans with a particular Klotho gene variant (KL-VS) also do modestly better on cognitive tests and may live longer. No one has yet turned this into a legitimate drug.

The KLOTHO gene encodes a single-pass transmembrane protein with two tandem extracellular β-glucuronidase-family domains (KL1 and KL2) that evolved from ancestral glycosidases and retain weak enzymatic activity on some substrates. Full-length membrane α-Klotho functions as an obligatory co-receptor with FGFR1c for FGF23, enabling the phosphaturic actions of FGF23 in the kidney. This membrane-bound function is the best-characterized canonical role and explains the severe phosphate-homeostasis phenotype of Klotho-null mice. A soluble form of Klotho (sKL) is generated by ADAM10/ADAM17-mediated cleavage of the extracellular domain or by alternative splicing that produces a secreted KL1-only variant. Soluble Klotho circulates in blood, urine, and CSF and has effects that appear distinct from FGF23 co-receptor function — inhibition of IGF-1 receptor and insulin receptor signaling at some doses, effects on Wnt signaling, modulation of TRPV5 calcium channels, sialidase activity on cell-surface glycoproteins, and effects on NMDA-receptor subunit composition in hippocampal synapses that may underlie cognitive effects. The exact receptor(s) mediating sKL's CNS effects remain incompletely characterized — some work implicates GluN2B-containing NMDA receptors downstream of peripheral sKL infusion, but a definitive 'Klotho receptor' distinct from FGFR/Klotho complexes has not been established. In humans, the KL-VS haplotype (F352V-C370S) alters secreted Klotho levels and the F352V substitution modestly alters KL1's sialidase activity. Heterozygotes have elevated serum Klotho and enhanced cognition; homozygotes have reduced Klotho and the opposite association — the heterozygote-advantage pattern that suggests balancing selection at the locus. Circulating Klotho declines with age in most measurements and is markedly reduced in chronic kidney disease, which is one of the most reproducible clinical observations in the field.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Klotho:

• 01Translation of the cognitive-enhancement effect from aged rodents and nonhuman primates to humans — no human therapeutic trial has read out.
• 02Whether the three registered human klotho trials can produce interpretable evidence at all. Two are uncontrolled pilots of 14 healthy adults, and all three run wholly or partly at a single clinic outside conventional regulatory jurisdiction. A positive readout from that design would not establish efficacy and a null would not establish futility — yet their mere existence is already being used in marketing as proof that klotho is in human trials.
• 03The molecular mechanism of soluble Klotho's CNS effects — candidate pathways (NMDA receptor modulation, anti-oxidative effects, IGF-1 modulation) are plausible but not consolidated. A 2026 Metabolic Brain Disease review frames α-Klotho as a 'central integrative signalling hub' for cognition and neuroprotection across Alzheimer's, Parkinson's, and broader neurodegeneration, but a single dominant mechanism has not emerged. A 2026 Scientific Reports conditional-knockout study found that deleting Klotho in dentate gyrus granule cells transiently reduced immature neurons (days 7–17 post-mitosis) but left stem-cell proliferation and long-term neuronal survival intact — so locally produced Klotho is not required for adult-born neurons to mature and integrate, which narrows adult hippocampal neurogenesis as a candidate route without eliminating it.
• 04Whether the KL-VS heterozygote advantage reflects Klotho protein itself or linked genetic architecture.
• 05Whether chronic Klotho elevation produces compensatory physiological adaptations that blunt long-term benefit.
• 06The pharmacokinetics and bioavailability of any viable therapeutic Klotho formulation — the recombinant ectodomain is a large glycosylated protein with non-trivial PK properties. A 2026 pharmaceutical-sciences review frames this as the core reason no klotho therapy exists nearly three decades after discovery, separating confirmed developability barriers (renal handling, limited systemic persistence) from merely plausible ones (aggregation, immunogenicity, poor tissue penetration), and notes the pipeline is now dominated by gene-, mRNA- and antibody-based approaches rather than recombinant protein.
• 07Whether smaller Klotho-derived peptides can reproduce the ectodomain's activity. This is no longer purely aspirational: Klotho-derived peptide 1 (KP1) protected mice against cisplatin- and ischemia-reperfusion acute kidney injury by entering proximal tubular cells and stabilising the mitochondrial protein ATAD3A (2026). But the validated activity there is renal and mitochondrial — nothing shows a short klotho peptide reproduces the cognitive effects, and KP1 is not what grey-market vendors sell.
• 08Legitimate biomarker assays for circulating Klotho — current ELISAs show significant inter-method variability that complicates epidemiological and clinical interpretation.

Forms & Administration

No FDA-approved Klotho therapy exists. Academic research uses recombinant mouse or human α-Klotho (KL1 alone or KL1+KL2 ectodomain), produced in mammalian expression systems and administered by intraperitoneal injection in rodents or subcutaneous injection in non-human primates. There is no legitimate source for recombinant sKL outside of research suppliers, and products sold in the biohacker market as 'Klotho peptide' are almost certainly not the same molecules as research-grade recombinant Klotho — the recombinant protein is 500+ amino acids and requires mammalian expression, not accessible to standard peptide-synthesis production. Serum α-Klotho measurement is available clinically (ELISA-based assays, though inter-assay variability is significant) and is principally useful in kidney-disease monitoring.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

There is no FDA-approved Klotho therapy. Grey-market 'Klotho peptide' products are not characterized pharmaceuticals. Nothing on this page constitutes a suggested self-use protocol.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Klotho Is NOT For

Drug & Supplement Interactions

No formal drug interaction data exists because no FDA-approved Klotho therapy exists. Theoretical considerations: Klotho modulates FGF23 signaling, which could interact with phosphate binders, active vitamin D analogs, and calcimimetics in CKD patients; Klotho inhibits IGF-1 and insulin receptor signaling at some doses, with theoretical implications for insulin and oral antihyperglycemic dosing; NMDA-receptor-mediated effects raise theoretical considerations around concurrent NMDA-acting drugs (memantine, ketamine) but no characterized interaction exists. The biohacker-market products' interaction profile is wholly uncharacterized.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions